publication date: Jan. 18, 2019
New MSK rules prohibit service on boards of for-profit entities in healthcare
By Paul Goldberg
An internal task force formed to investigate conflicts of interest at Memorial Sloan Kettering Cancer Center has produced three initial recommendations that codify the moratoria that were put in place after multiple ethics transgressions at the cancer center were revealed by The New York Times and ProPublica last fall.
The new rules were announced Jan 11 in a memo from Debra Berns, senior vice president and chief risk officer at MSK.
In addition to codifying earlier prohibitions, the rules constitute the cancer center’s direct response to the revelations that started to appear last September, causing the resignation of Physician-in-Chief José Baselga and causing President and CEO Craig Thompson to resign from boards of two healthcare companies.
The rules also restrict the ability by MSK board members to invest in spin-off companies and serve on their boards. Also, senior executive officers at the cancer center are prohibited from serving on the boards of for-profit companies.
The memo states that additional recommendations are likely to be brought forth, but even as it stands, the MSK policies will likely influence other cancer centers, potentially making it more difficult—or unacceptable—for senior officials elsewhere to serve on boards of pharma companies and other for-profit … Continue reading New MSK rules prohibit service on boards of for-profit entities in healthcare
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.